Evidence map›Paper›PMID 41050406›Full record

ArticleFrontiers in pharmacology2025

Prevalence of risk phenotypes associated with

Mohitosh Biswas, Murshadul Alam Murad, Maliheh Ershadian, Most Sumaiya Khatun Kali, Maw Shin Sim, Baharudin Ibrahim, Chonlaphat Sukasem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Predictor Role ofMedicina (Kaunas, Lithuania) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohitosh Biswas *Department of Pharmacy, Faculty of Science, University of Rajshahi, Rajshahi, Bangladesh.
Murshadul Alam Murad *Department of Pharmacy, Faculty of Science, University of Rajshahi, Rajshahi, Bangladesh.
Maliheh ErshadianDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Most Sumaiya Khatun KaliDepartment of Pharmacy, Daffodil International University, Dhaka, Bangladesh.
Maw Shin SimDepartment of Pharmaceutical Life Sciences, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
Baharudin IbrahimDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
Chonlaphat SukasemDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The safety or efficacy of drugs may be affected by the genetic variability of Methods: The allele frequencies of Results: Intermediate and poor metabolizers were predicted to be risk phenotypes (17.8%; 95% CI 16.3%-19.3%) due to inheriting Conclusion: To enhance the safety of at least 11 clinically significant drugs, the current study found that approximately one-fifth of the global population is at risk based on the

Indexed as

clinical practiceCYP2C9efficacygenetic polymorphismspharmacogenomicsprecision medicinesafetyVKORC1

Identifiers

PMID41050406
PMCPMC12491204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.